Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism

被引：0
|
作者：
Bo Xie
Ying Qiu
Juan Zhou
Dou Du
Haochuan Ma
Jiapeng Ji
Liquan Zhu
Weimin Zhang
机构：
[1] General Hospital of Southern Theater Command,Department of Oncology
[2] PLA,undefined
来源：
Clinical and Translational Oncology | 2022年 / 24卷
关键词：
Lorlatinib resistance; Non-small cell lung cancer; -; Mechanism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2231 / 2240
页数：9
相关论文
共 50 条
  • [31] Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer.
    Lin, Jessica Jiyeong
    Johnson, Ted
    Lennerz, Jochen K.
    Lee, Charlotte
    Hubbeling, Harper Grace
    Yeap, Beow Y.
    Dagogo-Jack, Ibiayi
    Gainor, Justin F.
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Overcoming the Acquired Resistance to Afatinib (BIBW2992) in HCC827, a Non-small Cell Lung Cancer Cell Line
    Hsu, J.
    Lin, W.
    Lien, T.
    Yen, K.
    Chang, W.
    Jiang, S.
    Chao, Y.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S129 - S129
  • [33] Adaptive resistance to lorlatinib by EGFR activation in ALK-rearranged non-small cell lung cancer cells
    Katayama, Yuki
    Tanimura, Keiko
    Morimoto, Kenji
    Horinaka, Mano
    Sakai, Toshiyuki
    Ozasa, Hiroaki
    Yamada, Tadaaki
    CANCER SCIENCE, 2023, 114 : 1474 - 1474
  • [34] Adaptive resistance to lorlatinib by EGFR activation in ALK-rearranged non-small cell lung cancer cells
    Katayama, Yuki
    Tanimura, Keiko
    Morimoto, Kenji
    Horinaka, Mano
    Sakai, Toshiyuki
    Ozasa, Hiroaki
    Yamada, Tadaaki
    CANCER SCIENCE, 2023, 114 : 830 - 830
  • [35] LORLATINIB IS ACTIVE IN ROS1-POSITIVE NON-SMALL CELL LUNG CANCER
    不详
    CANCER DISCOVERY, 2020, 10 (01) : 12 - 12
  • [36] Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer
    Choo, Joan Rou-En
    Soo, Ross A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (04) : 233 - 240
  • [37] Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
    Mogenet, Alice
    Tomasini, Pascale
    Greillier, Laurent
    Barlesi, Fabrice
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S383 - S386
  • [38] Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells
    Deben, Christophe
    Boullosa, Laurie Freire
    Domen, Andreas
    Wouters, An
    Cuypers, Bart
    Laukens, Kris
    Lardon, Filip
    Pauwels, Patrick
    CANCER DRUG RESISTANCE, 2021, 4 (01) : 233 - 243
  • [39] Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line
    Lei, Zi-Ning
    Teng, Qiu-Xu
    Zhang, Wei
    Fan, Ying-Fang
    Wang, Jing-Quan
    Cai, Chao-Yun
    Lu, Kimberly W.
    Yang, Dong-Hua
    Wurpel, John N. D.
    Chen, Zhe-Sheng
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [40] Role of ERK reactivation mediated by Src in acquired resistance to gefitinib in non-small cell lung cancer with EGFR mutation
    Ochi, Nobuaki
    Takigawa, Nagio
    Ohashi, Kadoaki
    Takeda, Hiromasa
    Fujii, Masanori
    Kubo, Toshio
    Ichihara, Eiki
    Hotta, Katsuyuki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CANCER RESEARCH, 2011, 71
12345